Arrowhead Pharmaceuticals

This study tested a new drug called fazirsiran in 16 people with alpha-1 antitrypsin deficiency (AATD) liver disease. The goal was to see if the drug is safe and can reduce harmful protein buildup in the liver. Participants received multiple doses, and researchers measured change…

This study tested an experimental drug called ARO-HSD in 50 people, including healthy volunteers and patients with NASH (a serious fatty liver disease). The main goal was to check safety and how the drug moves through the body. Researchers gave single or multiple doses to see if …

This early-stage study tested an inhaled drug called ARO-MMP7 in 105 people, including healthy volunteers and patients with idiopathic pulmonary fibrosis (IPF), a lung-scarring disease. The main goal was to check safety and how the drug moves through the body. Researchers also me…

This study tested an experimental drug called ARO-HBV in 114 people, including healthy volunteers and patients with chronic hepatitis B. The main goal was to check if the drug is safe and how the body processes it. Researchers gave single or multiple doses and monitored side effe…

This study tested a new drug called plozasiran in 353 adults with mixed dyslipidemia, a condition where both cholesterol and triglycerides are high. Participants received either the drug or a placebo for 48 weeks while staying on a healthy diet. The goal was to see if plozasiran …

This study looked at the long-term safety of a drug called ARO-APOC3 in 418 adults with dyslipidemia (abnormal fat levels in the blood). Participants who completed a previous 12-month study received the drug every 3 or 6 months. The main goal was to track side effects, and the st…

This study tested an experimental drug called ARO-APOC3 in 229 adults with severely high triglycerides (a type of blood fat). Participants received two injections of the drug or a placebo. The goal was to see if the drug safely lowers triglyceride levels and reduces related prote…

This study tested an experimental drug called ARO-ANG3 in 204 adults with mixed dyslipidemia, a condition where blood fats like triglycerides and cholesterol are too high. Participants received injections of the drug or a placebo to see if it safely lowers these fats. The goal is…

This study tested an experimental drug called fazirsiran in 40 adults with alpha-1 antitrypsin deficiency, a genetic condition that can cause liver and lung damage. The goal was to see if the drug safely lowers levels of a harmful protein (Z-AAT) in the blood. Participants receiv…

This early-stage study tested a new drug called ARO-ANG3 in 93 healthy adults and patients with high cholesterol or high triglycerides. The main goal was to check safety and how the drug moves through the body. Researchers gave single or multiple doses to see if it could help con…

This early-stage study tested a new medicine called ARO-APOC3 in healthy people and those with extremely high triglycerides, including a rare genetic condition called familial chylomicronemia syndrome. The main goal was to check safety and how the drug moves through the body. 112…

This early-stage trial tested a new drug called ARO-HIF2 in 26 people with advanced clear cell kidney cancer that had worsened after at least two prior treatments. The goal was to find a safe dose and see if the drug could help control the disease. Researchers monitored side effe…

This study tested a new drug called ARO-C3 in healthy volunteers and people with kidney diseases caused by an overactive immune system (C3 Glomerulopathy and IgA Nephropathy). The main goal was to check the drug's safety and how it moves through the body. Participants received on…

This study tested an inhaled drug called ARO-RAGE in 127 healthy volunteers and people with asthma. The goal was to see if it is safe and how it affects lung function. Participants received one or two doses of the drug or a placebo. The results will help decide if further testing…

This early-stage study tested a new drug called ARO-AAT in 45 healthy adults to see if it is safe and how the body processes it. The goal was to gather information for future studies in people with Alpha-1 Antitrypsin Deficiency, a genetic condition that can harm the lungs and li…

This early-stage study tested the safety and how the body processes a single dose of ARC-520, given at different speeds, in 40 healthy adults. The main goal was to check for side effects and measure drug levels in the blood. Since participants were healthy, this study was not mea…

This early-stage study tested the safety and how the body processes ARC-520 in 54 healthy adults aged 18-55. Participants received either the drug or a placebo to check for side effects. The goal was not to treat any disease, but to gather important safety information for future …